Actavis sells off Chinese subsidiary


Generic drugs heavyweight Actavis is selling off a subsidiary based in Foshan, China. The business is being bought by Zhejiang Chiral Medicine Chemicals for an undisclosed sum.

In a company statement, Actavis stressed that the company ‘intends to continue further commercial operations in China in collaboration with its preferred business partners’. But in an interview with Bloomberg, chief executive Paul Bisaro claimed that doing business in China is ‘too risky’, and the returns were not worth the effort compared to other markets.


Related Content

Allergan steps away from generics with sale to Teva

29 July 2015 Business

news image

$40.5 billion deal gives Allergan cash to clear debt and fund further acquisitions, and catapults Teva into global pharma top...

UCB sells speciality generics subsidiary

26 November 2014 Business

news image

Firm will use $1.5bn proceeds to reduce debt and concentrate on developing new drugs in neurology and immunology

Most Commented

New antibiotic picked from nose bacteria

27 July 2016 Research

news image

Discovery suggests human microbiome may be an untapped source of antimicrobial compounds

Perovskite boosts silicon solar cell efficiency

25 November 2015 News and Analysis

news image

Silicon industry will be ‘beating a path to the door’ of inventors, says scientist